Sevelamer: Difference between revisions
CSV import |
CSV import |
||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
<gallery> | |||
File:Sevelamer.png|Sevelamer | |||
</gallery> | |||
<gallery> | <gallery> | ||
File:Sevelamer.png|Sevelamer | File:Sevelamer.png|Sevelamer | ||
</gallery> | </gallery> | ||
Revision as of 01:42, 20 February 2025
Sevelamer is a phosphate binding drug used to prevent hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was approved by the U.S. Food and Drug Administration (FDA) on October 30, 1998.
Mechanism of Action
Sevelamer operates by binding to dietary phosphate in the digestive tract and preventing its absorption into the body. This action helps to control serum phosphorus levels in patients with chronic kidney disease, particularly those on dialysis.
Uses
Sevelamer is primarily used to control hyperphosphatemia in patients with chronic kidney disease. It is often prescribed to patients on dialysis, as these individuals can have difficulty controlling their serum phosphorus levels.
Side Effects
Common side effects of sevelamer include nausea, vomiting, diarrhea, and abdominal pain. Less common side effects can include itching, rash, and shortness of breath.
Interactions
Sevelamer can interact with other medications, including levothyroxine and ciprofloxacin. It is important for patients to inform their healthcare provider of all medications they are currently taking.
